L&K BIOMED LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,720 KRW | +2.86% |
|
-0.61% | -4.52% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.52% | 143M | - | ||
| +13.31% | 129B | A- | ||
| -9.60% | 10.92B | A- | ||
| -2.59% | 8.5B | C | ||
| +37.50% | 5.5B | B+ | ||
| -22.36% | 4.69B | C | ||
| -11.25% | 2.73B | B- | ||
| -14.85% | 2B | - | - | |
| -13.29% | 1.93B | - | ||
| -28.75% | 1.65B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- A156100 Stock
- Ratings L&K Biomed Ltd.
